Eris Lifesciences to Acquire Remaining 30% Stake in Subsidiary Swiss Parenterals Limited for INR 423.3 Crores

Eris Lifesciences Ltd. has announced that its Board of Directors approved the acquisition of the remaining 30% of the total share capital of Swiss Parenterals Limited, a subsidiary of the Company, from Mr. Naishadh Shah for a total purchase consideration of INR 423,30,00,000. The acquisition will be discharged by the Company by way of issuance of up to 23,06,372 equity shares of the Company on a preferential basis to Mr. Naishadh Shah. Swiss Parenterals Limited is a pharmaceuticals company incorporated on February 04, 1997, with a history of last 3 years turnover (Group Level) of INR 220.80 crores, INR 282.97 crores, and INR 351.11 crores for FY 2022-23, FY 2023-24, and FY 2024-25, respectively. The acquisition is expected to complete prior to March 31, 2026.